Skip to main content
placeholder image

A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC):  NCIC Clinical Trials Group study BR29.

Journal Article


Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2012

Citation


  • Laurie, S. A., Solomon, B. J., Seymour, L., Ellis, P. M., Goss, G. D., Shepherd, F. A., . . . Bradbury, P. A. (2012). A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC):  NCIC Clinical Trials Group study BR29.. Journal of Clinical Oncology, 30(15_suppl), 7511. doi:10.1200/jco.2012.30.15_suppl.7511

Web Of Science Accession Number


Start Page


  • 7511

End Page


  • 7511

Volume


  • 30

Issue


  • 15_suppl

Abstract


UOW Authors


  •   Clingan, Phillip (external author)

Publication Date


  • 2012

Citation


  • Laurie, S. A., Solomon, B. J., Seymour, L., Ellis, P. M., Goss, G. D., Shepherd, F. A., . . . Bradbury, P. A. (2012). A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC):  NCIC Clinical Trials Group study BR29.. Journal of Clinical Oncology, 30(15_suppl), 7511. doi:10.1200/jco.2012.30.15_suppl.7511

Web Of Science Accession Number


Start Page


  • 7511

End Page


  • 7511

Volume


  • 30

Issue


  • 15_suppl